"10.1371_journal.pone.0034372","plos one","2012-04-12T00:00:00Z","Tara L Kieffer; Sandra De Meyer; Doug J Bartels; James C Sullivan; Eileen Z Zhang; Ann Tigges; Inge Dierynck; Joan Spanks; Jennifer Dorrian; Min Jiang; Bambang Adiwijaya; Anne Ghys; Maria Beumont; Robert S Kauffman; Nathalie Adda; Ira M Jacobson; Kenneth E Sherman; Stefan Zeuzem; Ann D Kwong; Gaston Picchio","Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America; Janssen Infectious Diseases BVBA, Beerse, Belgium; Weill Cornell Medical College, New York, New York, United States of America; University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America; Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; Janssen Research and Development, Titusville, New Jersey, United States of America","Conceived and designed the experiments: TLK SDM DJB JCS MB RSK NA IMJ KES SZ ADK GP. Performed the experiments: EZZ AT JS JD MJ. Analyzed the data: TLK SDM DJB JCS ID MJ BA AG. Wrote the paper: TLK DJB JCS.","The authors have read the journal's policy and have the following conflicts: TLK, DJB, JCS, EZZ, AT, JS, JD, MJ, RSK, NA, and ADK are employees and stock owners of Vertex Pharmaceuticals Incorporated. BA was an employee of Vertex Pharmaceuticals at the time this research was performed, is a current Vertex stock owner, and is a current employee of Merrimack Pharmaceuticals. SDM, ID, AG, MB, and GP are employees of Janssen Pharmaceuticals and stock owners of Johnson & Johnson. IMJ has received consulting and lecture fees from Abbott, Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlobeImmune, Human Genome Sciences, Novartis, Pharmasset, Pfizer, Roche/Genentech, Sanofi-Aventis, Schering-Plough/Merck, Tibotec, Vertex Pharmaceuticals Incorporated, and ZymoGenetics; and grant/research support from Anadys Pharmaceuticals, Boehringer Ingelheim, Gilead Sciences, GlobeImmune, Human Genome Sciences, Novartis, Pharmasset, Roche/Genentech, Schering-Plough/Merck, Tibotec, and Vertex Pharmaceuticals Incorporated. KES has received grant/research support from Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Merck, Pharmasset, Schering-Plough and Vertex Pharmaceuticals; and is an Advisory or Review Committee Member for Bristol-Myers Squibb, Merck, Pfizer, Fibrogen, Genentech, Tibotec, and Vertex Pharmaceuticals. SZ has received consulting/lecture fees from Abbott, Achillion, Anadys Pharmaceuticals, Bayer, Bristol-Myers Squibb, Gilead Sciences, Human Genome Sciences, Novartis, Pharmasset, Roche/Genentech, Santaris, Schering-Plough/Merck, Tibotec and Vertex Pharmaceuticals. None of the aforementioned commercial grant/research support was used for this specific study. Telaprevir was used in this study and is a drug that was co-developed by Vertex and Johnson. There are no other patents, products in development, or other marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2012","04","Tara L Kieffer","TLK",20,TRUE,12,5,8,3,TRUE,TRUE,FALSE,0,NA,FALSE
